21 May 2009
Dyslipidaemia in lung transplant recipients during short and long term follow UP
S Zeglen, J Wojarski, E Wozniak-Grygiel, R Buldak, E Kucewicz, M ZembalaAnn Transplant 2009; 14(1): 61-61 :: ID: 880421
Abstract
Background: Hypercholesterolemia is a frequent complication in lung transplant recipients but the mechanisms contributing to its development are not exactly known.
Material/Methods: Total cholesterol levels (Chol, [mmol/L]) as well as lipoproteins like HDL (mmol/L), LDL (mmol/L) and TG, (mmol/L) were retrospectively analysed in 15 lung transplant recipients (2 women and 13 men, mean age 46.2±12.1, BMI 20.5±4.2) in various post-transplantation periods (early-eTP up to 30 days and long-lTP up to two years after LTx). Lipoproteins were estimated using routine enzyme/colorimetric method (Cobas-Integra).
Results: In eTP period mean cholesterol value was 4.57±0.37 (in 23% of patients values were above normal); HDL was 1.03±0.19 (in 30.8% values were decreased); mean LDL value was 2.8±0.36 (30.8% values above the normal); TG 2.26±0.66 were upregulated (in 61.5% patients upper than normal). Mean cholesterol in late period (lTP) was 4.01±0.53 (in 16.7% patients above normal); HDL 1.25±0.23 (in 8.3% of subjects values were down-regulated); LDL was 2.49±0.54 (16.7% of patients presented increased values); TG were 1.55±0.43 (33.3% of patients had upper values than normal). There were no differences in lipid disturbances between studied periods. There was no difference in lipids between tacrolimus and cyclosporine groups with an exception of total cholesterol (4.09±0.4 vs. 4.92±0.97 p<0.05; HDL 1.14±0.26 vs. 1.23±0.21 p>0.05; LDL 2.36±0.45 vs. 3.07±0.73 p>0.05; TG 1.48±0.47 vs. 2.25±0.57).
Conclusions: Clinically significant percentage of patients presented atherogenic constellation of lipoproteins -high TG, LDL and low HDL. It could also be
concluded that tacrolimus might be less atherogenic than cyclosporine.
Keywords: Lung Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






